4.7 Review

Canadian Network for Mood and Anxiety Treatments (CANMAT) Clinical guidelines for the management of major depressive disorder in adults. V. Complementary and alternative medicine treatments

Journal

JOURNAL OF AFFECTIVE DISORDERS
Volume 117, Issue -, Pages S54-S64

Publisher

ELSEVIER
DOI: 10.1016/j.jad.2009.06.040

Keywords

Major depressive disorder; Canadian Network for Mood and Anxiety Treatments (CANMAT); Complimentary and Alternative Medicine Light therapy; Exercise therapy; Nutraceutical therapies

Funding

  1. Canadian Network for Mood and Anxiety Treatments
  2. AstraZeneca
  3. Cephalon
  4. Eli Lilly
  5. GlaxoSmithKline
  6. Janssen-Ortho
  7. Lundbeck
  8. Pfizer
  9. Roche
  10. Servier
  11. Wyeth
  12. Advanced Neuromodulation Systems Inc.
  13. BrainCells Inc.
  14. Biovail
  15. Canadian Institutes of Health Research
  16. Canadian Psychiatric Research Foundation
  17. Janssen
  18. Litebook Company Ltd.
  19. Lundbeck Institute
  20. Mathematics of Informatics Technology and Advanced Computing Systems
  21. Michael Smith Foundation for Health Research
  22. Takeda
  23. UBC Institute of Mental Health/Coast Capital Savings
  24. Bristol-Myers-Squibb
  25. Janssen Ortho
  26. Servier Canada
  27. Isodis Natura
  28. Advanced Neuromodulation Systems Inc
  29. Boehringer-Ingelhem
  30. Brain Cells Inc
  31. Merck Frost
  32. Apotex
  33. Lilly
  34. Novartis
  35. Cipher Pharmaceuticals
  36. Norlein Foundation

Ask authors/readers for more resources

Background: In 2001, the Canadian Psychiatric Association and the Canadian Network for Mood and Anxiety Treatments (CANMAT) partnered to produce evidence-based clinical guidelines for the treatment of depressive disorders. A revision of these guidelines was undertaken by CANMAT in 2008-2009 to reflect advances in the field. There is widespread interest in complementary and alternative medicine (CAM) therapies in the treatment of major depressive disorder (MDD). Methods: The CANMAT guidelines are based on a question-answer format to enhance accessibility to clinicians. An evidence-based format was used with updated systematic reviews of the literature and recommendations were graded according to Level of Evidence using pre-defined criteria Lines of Treatment were identified based on criteria that included evidence and expert clinical support. This section on Complementary and Alternative Medicine Treatments is one of 5 guideline articles. Results: There is Level 1 evidence to support light therapy in seasonal MDD and St. John's wort in mild to moderate MDD. There is also some evidence for the use of exercise, yoga and sleep deprivation, as well as for omega-3 fatty acids and SAM-e. Support for other natural health products and therapies is still limited. Limitations: The evidence base remains limited and studies often have methodological problems, including small samples, variability in dose, short duration of treatment, unknown quality of the agent and limited long-term data. Safety data are also sparse with little information about drug interactions. Conclusions: Some CAM treatments have evidence of benefit in MDD. However, problems with standardization and safety concerns may limit their applicability in clinical practice. (C) 2009 Published by Elsevier B.V.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available